SCHEMBL6534967

SCHEMBL6534967

CCCCC[C@H](F)[C@@H](F)COc1cnc(-c2ccc(OCCCC[Si](C)(C)CCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F)cc2)nc1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.38
RAB9A P51151 4/20 0.38
KDM4E B2RXH2 4/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HSD17B10 Q99714 1/20 0.38
MAPT P10636 1/20 0.35
ALDH1A1 P00352 3/20 0.31
CYP2C9 P11712 5/20 0.31
CYP2C19 P33261 5/20 0.31
CYP2D6 P10635 4/20 0.31
CYP19A1 P11511 4/20 0.31
CYP1A2 P05177 2/20 0.31
PLA2G4B P0C869 1/20 0.31
PLA2G2A P14555 2/20 0.30
RARB P10826 3/20 0.30
CYP3A4 P08684 2/20 0.30
HPGD P15428 2/20 0.30
HTT P42858 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6534966 1.00 NPC1 (0.38) NPC1RAB9AKDM4ESMN1; SMN2HSD17B10
SCHEMBL6534787 0.89 NPC1 (0.44) NPC1RAB9AKDM4ESMN1; SMN2HSD17B10
SCHEMBL6535033 0.89 NPC1 (0.44) NPC1RAB9AKDM4ESMN1; SMN2HSD17B10
SCHEMBL6534955 0.88 NPC1 (0.45) NPC1RAB9AKDM4ESMN1; SMN2HSD17B10
SCHEMBL6534705 0.84 NPC1 (0.39) NPC1RAB9AKDM4ESMN1; SMN2HSD17B10
SCHEMBL6535070 0.82 RARB (0.43) NPC1RAB9AKDM4ESMN1; SMN2HSD17B10
SCHEMBL6017546 0.82 NPC1 (0.46) NPC1RAB9AKDM4ESMN1; SMN2HSD17B10
SCHEMBL14570058 0.81 NPC1 (0.52) NPC1RAB9AKDM4ESMN1; SMN2HSD17B10
SCHEMBL6535039 0.81 NPC1 (0.36) NPC1RAB9AKDM4ESMN1; SMN2HSD17B10
SCHEMBL6534731 0.80 NPC1 (0.38) NPC1RAB9AKDM4ESMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6737124-B2 ESPECIALLY DISILANES DISPLAYTECH, INC. 2004-05-18 US disclosed
US-20030003245-A1 Liquid crystal compounds having a silane tail with a perfluoroalkyl terminal portion CITIZEN FINETECH MIYOTA CO., LTD. (JP) 2003-01-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030003245-A1 Liquid crystal compounds having a silane tail with a perfluoroalkyl terminal portion FFAR3, FFAR1, LPAR1 NPC1 393/4885RAB9A 1832/4885KDM4E 2549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.